vTv Therapeutics (NASDAQ:VTVT) Research Coverage Started at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Rating) in a research report issued on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of vTv Therapeutics in a report on Tuesday, March 7th.

vTv Therapeutics Stock Up 11.0 %

VTVT stock opened at $0.85 on Friday. The stock has a 50-day simple moving average of $0.80 and a two-hundred day simple moving average of $0.82. vTv Therapeutics has a twelve month low of $0.50 and a twelve month high of $1.40. The firm has a market capitalization of $89.39 million, a PE ratio of -4.07 and a beta of -1.20.

vTv Therapeutics (NASDAQ:VTVT – Get Rating) last posted its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. On average, equities research analysts anticipate that vTv Therapeutics will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On vTv Therapeutics

Large investors have recently made changes to their positions in the company. Millennium Management LLC boosted its holdings in shares of vTv Therapeutics by 12.0% in the 2nd quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 14,845 shares in the last quarter. Prudential Financial Inc. acquired a new position in vTv Therapeutics during the 2nd quarter valued at about $30,000. HBK Sorce Advisory LLC purchased a new stake in vTv Therapeutics in the fourth quarter valued at about $38,000. Finally, State Street Corp boosted its holdings in vTv Therapeutics by 268.7% in the second quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 150,228 shares in the last quarter. 8.50% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

(Get Rating)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer.